Epicrispr, Infinimmune snag combined $165M in VC cash
Epicrispr Biotechnologies is working on an epigenetic medicine for facioscapulohumeral muscular dystrophy, while Infinimmune will advance a pair of antibodies for atopic dermatitis.
Infinimmune
Private
Development of drugs from complete human antibodies. Surfaces and engineers rare antibodies from human biology for autoimmune diseases. Raised $75M Series A backed by Regeneron Ventures.
Company Info
Sector:Antibody Therapeutics / Autoimmune Disease
Headquarters:South San Francisco, California, USA
Founded:2022
Website:www.infinimmune.com/
Funding Round:Series A ($75M)
Total Funding:$75M
Funding & Investor Relations
Notable Investors
- Regeneron Ventures
- ARCH Venture Partners
- GV
Upcoming Milestones & Key Dates
2027
Regulatory
Lead program IND filing expected
Clinical Development Pipeline
INF-001
Target: Rare human antibodyRecent News
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
Lilly paid $2B upfront for vaccine biotechs; Infinimmune raises $75M
Regeneron backs $75M series A for antibody upstart Infinimmune
Regeneron backs $75M series A for antibody upstart Infinimmune
Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs
Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs
Leadership Team
Scott Breslau
Chief Executive Officer
Vicki Sato
Chairwoman of the Board
Timothy Lu
Chief Scientific Officer